Neumora Therapeutics (NMRA) Competitors

$1.85 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$1.90 +0.05 (+2.97%)

As of 05/22/2026 07:19 PM Eastern

NMRA vs. BCAX, BHVN, SLS, WVE, and AVBP

Should you buy Neumora Therapeutics stock or one of its competitors? MarketBeat compares Neumora Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neumora Therapeutics include Bicara Therapeutics (BCAX), Biohaven (BHVN), SELLAS Life Sciences Group (SLS), WAVE Life Sciences (WVE), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical products" industry.

How does Neumora Therapeutics compare to Bicara Therapeutics?

Bicara Therapeutics (NASDAQ:BCAX) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

47.7% of Neumora Therapeutics shares are held by institutional investors. 15.5% of Bicara Therapeutics shares are held by company insiders. Comparatively, 26.9% of Neumora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Bicara Therapeutics has a beta of -0.57, indicating that its stock price is 157% less volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 3.02, indicating that its stock price is 202% more volatile than the broader market.

Bicara Therapeutics' return on equity of -35.89% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-35.89%	-33.78%
Neumora Therapeutics	N/A	-181.70%	-119.15%

Bicara Therapeutics currently has a consensus price target of $30.27, suggesting a potential upside of 39.63%. Neumora Therapeutics has a consensus price target of $7.67, suggesting a potential upside of 314.41%. Given Neumora Therapeutics' higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.56

In the previous week, Bicara Therapeutics had 10 more articles in the media than Neumora Therapeutics. MarketBeat recorded 11 mentions for Bicara Therapeutics and 1 mentions for Neumora Therapeutics. Bicara Therapeutics' average media sentiment score of 0.10 beat Neumora Therapeutics' score of -0.49 indicating that Bicara Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Neumora Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bicara Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A

Summary

Bicara Therapeutics beats Neumora Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Neumora Therapeutics compare to Biohaven?

Neumora Therapeutics (NASDAQ:NMRA) and Biohaven (NYSE:BHVN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 26.9% of Neumora Therapeutics shares are held by insiders. Comparatively, 13.8% of Biohaven shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Neumora Therapeutics presently has a consensus target price of $7.67, suggesting a potential upside of 314.41%. Biohaven has a consensus target price of $22.27, suggesting a potential upside of 135.75%. Given Neumora Therapeutics' higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.56
Biohaven	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.71

Neumora Therapeutics' return on equity of -181.70% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-181.70%	-119.15%
Biohaven	N/A	-866.46%	-137.99%

In the previous week, Neumora Therapeutics and Neumora Therapeutics both had 1 articles in the media. Biohaven's average media sentiment score of 0.59 beat Neumora Therapeutics' score of -0.49 indicating that Biohaven is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neumora Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biohaven	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biohaven is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A

Neumora Therapeutics has a beta of 3.02, suggesting that its stock price is 202% more volatile than the broader market. Comparatively, Biohaven has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market.

Summary

Neumora Therapeutics beats Biohaven on 8 of the 13 factors compared between the two stocks.

How does Neumora Therapeutics compare to SELLAS Life Sciences Group?

Neumora Therapeutics (NASDAQ:NMRA) and SELLAS Life Sciences Group (NASDAQ:SLS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

SELLAS Life Sciences Group's return on equity of -47.12% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-181.70%	-119.15%
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%

Neumora Therapeutics has a beta of 3.02, suggesting that its share price is 202% more volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.24, suggesting that its share price is 124% more volatile than the broader market.

47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 26.9% of Neumora Therapeutics shares are held by company insiders. Comparatively, 1.4% of SELLAS Life Sciences Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Neumora Therapeutics currently has a consensus target price of $7.67, suggesting a potential upside of 314.41%. SELLAS Life Sciences Group has a consensus target price of $10.00, suggesting a potential upside of 28.53%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Neumora Therapeutics is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.56
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A

In the previous week, SELLAS Life Sciences Group had 4 more articles in the media than Neumora Therapeutics. MarketBeat recorded 5 mentions for SELLAS Life Sciences Group and 1 mentions for Neumora Therapeutics. SELLAS Life Sciences Group's average media sentiment score of 0.32 beat Neumora Therapeutics' score of -0.49 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neumora Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
SELLAS Life Sciences Group	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Neumora Therapeutics beats SELLAS Life Sciences Group on 8 of the 14 factors compared between the two stocks.

How does Neumora Therapeutics compare to WAVE Life Sciences?

WAVE Life Sciences (NASDAQ:WVE) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

WAVE Life Sciences has a beta of -1.32, indicating that its share price is 232% less volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 3.02, indicating that its share price is 202% more volatile than the broader market.

WAVE Life Sciences currently has a consensus price target of $27.25, suggesting a potential upside of 327.12%. Neumora Therapeutics has a consensus price target of $7.67, suggesting a potential upside of 314.41%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than Neumora Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.56

89.7% of WAVE Life Sciences shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 24.3% of WAVE Life Sciences shares are owned by insiders. Comparatively, 26.9% of Neumora Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, WAVE Life Sciences had 10 more articles in the media than Neumora Therapeutics. MarketBeat recorded 11 mentions for WAVE Life Sciences and 1 mentions for Neumora Therapeutics. WAVE Life Sciences' average media sentiment score of 0.07 beat Neumora Therapeutics' score of -0.49 indicating that WAVE Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neumora Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neumora Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. WAVE Life Sciences' return on equity of -56.76% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-255.70%	-56.76%	-42.80%
Neumora Therapeutics	N/A	-181.70%	-119.15%

WAVE Life Sciences has higher revenue and earnings than Neumora Therapeutics. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	28.73	-$204.38M	-$1.06	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A

Summary

WAVE Life Sciences beats Neumora Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Neumora Therapeutics compare to ArriVent BioPharma?

Neumora Therapeutics (NASDAQ:NMRA) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 26.9% of Neumora Therapeutics shares are held by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Neumora Therapeutics presently has a consensus target price of $7.67, suggesting a potential upside of 314.41%. ArriVent BioPharma has a consensus target price of $43.13, suggesting a potential upside of 61.34%. Given Neumora Therapeutics' higher probable upside, equities research analysts clearly believe Neumora Therapeutics is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.56
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Neumora Therapeutics has a beta of 3.02, indicating that its share price is 202% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market.

ArriVent BioPharma is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

In the previous week, Neumora Therapeutics had 1 more articles in the media than ArriVent BioPharma. MarketBeat recorded 1 mentions for Neumora Therapeutics and 0 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.00 beat Neumora Therapeutics' score of -0.49 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Neumora Therapeutics	Neutral
ArriVent BioPharma	Neutral

ArriVent BioPharma's return on equity of -48.98% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-181.70%	-119.15%
ArriVent BioPharma	N/A	-48.98%	-45.44%

Summary

Neumora Therapeutics and ArriVent BioPharma tied by winning 7 of the 14 factors compared between the two stocks.

Get Neumora Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NMRA vs. The Competition

Export

Metric	Neumora Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$342.78M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-1.39	18.74	21.21	25.65
Price / Sales	N/A	323.98	554.38	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	4.87	7.09	10.37	7.14
Net Income	-$236.93M	$24.45M	$3.57B	$335.98M
7 Day Performance	10.78%	6.38%	6.40%	4.15%
1 Month Performance	-17.78%	2.43%	3.53%	2.54%
1 Year Performance	172.18%	62.98%	34.04%	35.06%

Neumora Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NMRA Neumora Therapeutics	2.8758 of 5 stars	$1.85 flat	$7.67 +314.4%	+172.2%	$342.78M	N/A	N/A	108
BCAX Bicara Therapeutics	2.4419 of 5 stars	$19.29 -4.6%	$30.27 +56.9%	+133.9%	$1.33B	N/A	N/A	32	Analyst Upgrade Gap Up
BHVN Biohaven	2.5784 of 5 stars	$8.50 -3.0%	$22.27 +162.1%	-39.7%	$1.32B	N/A	N/A	239
SLS SELLAS Life Sciences Group	1.583 of 5 stars	$7.29 +3.0%	$10.00 +37.2%	+311.6%	$1.32B	N/A	N/A	10	Gap Up
WVE WAVE Life Sciences	3.1437 of 5 stars	$6.40 -5.5%	$27.50 +329.7%	+7.2%	$1.30B	$42.73M	N/A	240

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NMRA) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neumora Therapeutics (NMRA) Competitors

NMRA vs. BCAX, BHVN, SLS, WVE, and AVBP

How does Neumora Therapeutics compare to Bicara Therapeutics?

Summary

How does Neumora Therapeutics compare to Biohaven?

Summary

How does Neumora Therapeutics compare to SELLAS Life Sciences Group?

Summary

How does Neumora Therapeutics compare to WAVE Life Sciences?

Summary

How does Neumora Therapeutics compare to ArriVent BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMRA vs. The Competition

Neumora Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neumora Therapeutics (NMRA) Competitors

NMRA vs. BCAX, BHVN, SLS, WVE, and AVBP

How does Neumora Therapeutics compare to Bicara Therapeutics?

Do insiders & institutionals hold more shares of BCAX or NMRA?

Which has more risk & volatility, BCAX or NMRA?

Is BCAX or NMRA more profitable?

Do analysts prefer BCAX or NMRA?

Does the media refer more to BCAX or NMRA?

Which has higher earnings and valuation, BCAX or NMRA?

Summary

How does Neumora Therapeutics compare to Biohaven?

Do institutionals and insiders have more ownership in NMRA or BHVN?

Do analysts recommend NMRA or BHVN?

Is NMRA or BHVN more profitable?

Does the media refer more to NMRA or BHVN?

Which has stronger earnings & valuation, NMRA or BHVN?

Which has more volatility and risk, NMRA or BHVN?

Summary

How does Neumora Therapeutics compare to SELLAS Life Sciences Group?

Is NMRA or SLS more profitable?

Which has more volatility and risk, NMRA or SLS?

Do insiders & institutionals hold more shares of NMRA or SLS?

Do analysts rate NMRA or SLS?

Which has stronger earnings & valuation, NMRA or SLS?

Does the media prefer NMRA or SLS?

Summary

How does Neumora Therapeutics compare to WAVE Life Sciences?

Which has more risk and volatility, WVE or NMRA?

Do analysts recommend WVE or NMRA?

Do institutionals and insiders hold more shares of WVE or NMRA?

Does the media favor WVE or NMRA?

Is WVE or NMRA more profitable?

Which has higher earnings & valuation, WVE or NMRA?

Summary

How does Neumora Therapeutics compare to ArriVent BioPharma?

Do insiders and institutionals believe in NMRA or AVBP?

Do analysts rate NMRA or AVBP?

Which has more risk and volatility, NMRA or AVBP?

Which has stronger valuation and earnings, NMRA or AVBP?

Does the media refer more to NMRA or AVBP?

Is NMRA or AVBP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMRA vs. The Competition

Neumora Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools